Cure Rate Joint Model for Time-to-Event Data and Longitudinal Tumor Burden with Potential Change Points
含潜在变点的生存时间与纵向肿瘤负荷治愈率联合模型
In non-small cell lung cancer (NSCLC) clinical trials, tumor burden (TB) is a key longitudinal biomarker for assessing treatment effects. Typically, standard-of-care (SOC) therapies and some novel interventions initially decrease TB; however, many patients subsequently experience an increase-indicating disease progression-while others show a continuous decline. In patients with an eventual TB increase, the change point marks the onset of progression and must occur before the…